Research and Development

Roche’s vemurafenib has proven one of the stars of the ASCO cancer conference by increasing overall survival in skin cancer …

Parexel and Icon have been chosen as Pfizer’s two long-term partners, in a move by the US pharma company to …

Johnson & Johnson has identified Japan as a key growth market for its pharma business as it outlines its strategic …

Since biotech first emerged in the UK in the late 1980s, the dream has always been for the country to …

Elan Corporation has signed a deal with US small molecule drug specialist Proteostasis Therapeutics to develop products for conditions such …

Eisai and University College London are to extend their partnership in neuroscience research. The Japanese company’s Neuroscience Product Creation Unit …

Mergers and acquisitions abound in our latest round-up of contract research sector news, as players try to achieve the global …

The first cheque has been written for the government-backed Stratified Medicine Innovation Platform (SMIP), set up last year to pump …

Pfizer’s investigational cancer drug axitinib significantly increased survival in kidney cancer patients when compared to Bayer’s standard treatment Nexavar. New …

A UK blood cancer charity is creating a network of clinical trial centres with backing from the NIHR Clinical Research …

Roche’s MetMab has shown huge promise in phase II trials in lung cancer – but only in patients with ‘high …

Takeda has acquired Swiss specialist pharma firm Nycomed, boosting its presence in emerging markets. The deal comes in at 9.6 …

Shire’s ambitions to build a regenerative medicine business will soon be realised following its $750 million acquisition of Advanced BioHealing. …

Penn Pharma has appointed Mark Dean-Netscher as its new chief operating officer. He has more than 20 years experience in …

Sanofi has signed a deal with Indian drug maker Glenmark Pharmaceuticals to develop a new treatment for Crohn’s Disease. The …